How to appeal a Premera Blue Cross c. difficile infection denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for c. difficile infection

Cited policy: BCBS Medical Policy on Vowst (Fecal Microbiota Spores, live-brpk)

Adult ≥18 yr. ≥1 CDI recurrence following completion of antibiotic treatment for prior episode. 4 capsules PO daily x 3 consecutive days, starting 2-4 days after final antibiotic dose. Not for treatment of active CDI.

How Premera Blue Cross denies c. difficile infection — and how to counter it

Where Premera Blue Cross pushes back: 1) Experimental / investigational; 2) Step therapy: try Rebyota first; 3) Reserved for multiply recurrent (≥3 episodes); 4) Long-term data insufficient.

Counter-arguments that hold up: Vowst was FDA-APPROVED on April 26, 2023 — the FIRST oral FDA-approved live microbiota therapeutic. Indication (per FDA label): prevention of recurrence of CDI in adults following antibacterial treatment for recurrent CDI (i.e., ≥1 prior recurrence — 2nd episode onward). Approval based on ECOSPOR III (Feuerstadt NEJM 2022;386(3):220-229) — 88% recurrence-free at 8 wk vs 60% placebo; 79% vs 53% at 6 mo. ECOSPOR IV open-label confirmatory data also in FDA dossier. AGA Living Guideline 2024 supports Vowst and Rebyota as parallel options based on patient preference (oral vs rectal) — no step-therapy hierarchy mandated. ACG 2021 endorses microbiota-based therapy after recurrent CDI.

What Premera Blue Cross typically denies for c. difficile infection

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For c. difficile infection, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the c. difficile infection treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Fidaxomicin (Dificid)
• Fidaxomicin extended-pulsed
• Vancomycin PO
• Vancomycin enema
• Bezlotoxumab (Zinplava)
• Rebyota

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.